A new team at the University of Warwick has been awarded £2.6 million to conduct Technology Assessment Reviews (TARs) on new treatments.
Warwick Evidence will be dedicated to assessing the value for money of new medical treatments and technologies on NICE’s behalf. Using this information, NICE will make decisions on whether to recommend technologies, including drugs, devices and diagnostics, for use nationally across the NHS.
The Warwick Evidence team, led by Dr Aileen Clarke and Dr Paul Sutcliffe from Warwick Medical School, is one of three new TAR teams across the country.
The multidisciplinary team will work collaboratively across several departments at the University of Warwick and will be supported by a senior team of clinical and methodological expert advisors at both local and national level.
Acting Dean of Warwick Medical School, Professor Martin Underwood, said: “We are absolutely delighted about Warwick Evidence. Assessing new technologies to make sure they provide value for money is a key function for NICE and for the NHS. The role that Warwick Evidence will play will be crucial in this.”